Oct 12 (Reuters) - BiVictriX Therapeutics PLC:
* EXTENDED SURVIVAL RATES REPORTED WITH BVX001 IN A PRE-CLINICAL MODEL OF ACUTE MYELOID LEUKAEMIA Source text for Eikon: Further company coverage:
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
11 GBX | +10.00% | -4.35% | +4.76% |
04-17 | Bivictrix granted FDA orphan drug status for rare cancer treatment | AN |
04-17 | BiVictriX Wins US FDA's Orphan Drug Status for Blood Cancer Treatment | MT |
Oct 12 (Reuters) - BiVictriX Therapeutics PLC:
* EXTENDED SURVIVAL RATES REPORTED WITH BVX001 IN A PRE-CLINICAL MODEL OF ACUTE MYELOID LEUKAEMIA Source text for Eikon: Further company coverage:
1st Jan change | Capi. | |
---|---|---|
+4.76% | 11.54M | |
+44.48% | 55.07B | |
+43.57% | 40.22B | |
-0.86% | 41.79B | |
-7.59% | 28.17B | |
+12.30% | 26.28B | |
-21.83% | 18.93B | |
+7.15% | 13.03B | |
+29.40% | 12.26B | |
+25.15% | 12.21B |